NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

NovaBridge (Nasdaq: NBP) will host a virtual business update on March 9, 2026 at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).

Rhea-AI Summary

NovaBridge (Nasdaq: NBP) will host a virtual business update on March 9, 2026 at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in wet age-related macular degeneration (wet AMD).

VIS-101 is a bispecific dual VEGF-A/ANG-2 inhibitor in a randomized, dose-ranging Phase 2a study. NovaBridge is majority shareholder of Visara, which holds global rights to VIS-101 outside Greater China and certain Asian territories. The live webcast and a replay (archived ≥90 days) will be available via the company's News & Events page.

Argus Mar 3 session

-7.25% close to close Open Argus

Details

News Market Reaction – NBP

In the Mar 3 session, NBP declined 7.25%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A negative reaction despite an anticipated...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite an anticipated Phase 2a business update would have echoed prior instances where strong data, such as givastomig results on Jan 06, coincided with an -11.21% move. With the stock trading below the 200-day MA at $3.89, technical pressure and prior volatility around data events could amplify downside. In that context, disappointment around VIS-101’s profile or concerns about execution could have outweighed the strategic signaling of the call itself.

Key Figures

Phase: Phase 2a Business update date: March 9, 2026 Call time: 9:00 AM ET +1 more

Phase

Phase 2a

VIS-101 randomized, dose-ranging wet AMD study

Business update date

March 9, 2026

VIS-101 Phase 2a data business update call

Call time

9:00 AM ET

Start time for the virtual business update call

Webcast archive

90 days

Replay of the webcast to be available for at least 90 days

Historical Context

5 past events · Latest: Mar 02

5 events

1. Mar 02

   Conference appearance

   24h Move

   +5.2%

   Announcement of Leerink Global Healthcare Conference fireside chat and webcast access.

2. Feb 19

   Leadership change

   24h Move

   +0.9%

   Appointment of Emmett T. Cunningham Jr. as Vice Chairman and R&D Committee member.

3. Feb 17

   Clinical trial start

   24h Move

   +2.2%

   First patient dosed in global randomized Phase 2 study of givastomig in gastric cancer.

4. Jan 20

   Insider share purchases

   24h Move

   +5.1%

   Executive Chairman’s intent to buy up to $5,000,000 of ADSs in the open market.

5. Jan 06

   Clinical data update

   24h Move

   -11.2%

   Positive Phase 1b expansion data for givastomig in first-line metastatic gastric cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

vegf-a, ang-2, wet amd, diabetic macular edema, +3 more

7 terms

vegf-a medical

"purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential"

VEGF-A is a naturally occurring protein that acts like a growth signal for new blood vessels, helping tissues develop or repair their blood supply. It matters to investors because many drugs and diagnostics target or measure VEGF-A to treat conditions such as cancers and eye diseases, so changes in clinical trial results, regulatory decisions, or new therapies related to VEGF-A can directly affect the value and prospects of companies developing those treatments.

ang-2 medical

"purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential"

Ang-2 (angiopoietin-2) is a naturally occurring protein that helps control how blood vessels form, grow and leak by acting like a thermostat for vessel stability. Investors care because changes in Ang-2 levels are used as a biomarker in drug development and disease diagnosis—affecting clinical trial outcomes, regulatory decisions, and the commercial potential of therapies targeting blood vessel-related conditions, much like a warning light that guides treatment strategy and market value.

wet amd medical

"treatment than the current standard of care for patients with wet AMD, DME and RVO"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

diabetic macular edema medical

"standard of care for patients with wet AMD, DME and RVO Visara, a NovaBridge"

Diabetic macular edema is an eye condition in which fluid leaks into and swells the macula, the part of the retina used for sharp, central vision, often as a complication of diabetes. For investors it matters because it drives demand for medicines, medical devices and eye-care services, influences clinical trial and regulatory outcomes, and can affect healthcare costs and revenue forecasts—think of the macula as the camera’s central lens that becomes blurred when it soaks up excess fluid.

retinal vein occlusion medical

"treatment benefits for patients with wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO)."

Retinal vein occlusion is a blockage of one of the small veins that drain blood from the light-sensitive layer at the back of the eye, like a clogged pipe causing fluid and pressure to build up and damaging vision. For investors it matters because the condition drives demand for drugs, medical devices and procedures, influences clinical trial activity and regulatory decisions, and can materially affect revenue prospects for companies developing treatments or diagnostics.

bispecific medical

"VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

tetravalent medical

"VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor"

Tetravalent describes a product—commonly a vaccine or antibody treatment—that is designed to protect against or bind to four distinct strains or targets. For investors, tetravalent products can mean broader market appeal and potentially better protection compared with single-target options, but they may also face higher development, manufacturing and regulatory complexity; think of it like a four-in-one tool that covers more situations but can be harder and costlier to build.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO 

Visara, a NovaBridge Majority-Owned Subsidiary, Holds Global Rights to VIS-101 Outside of Greater China and Certain Asian Territories

ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that it will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD).

VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed to provide more potent and durable treatment benefits for patients with wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD.

NovaBridge is the majority shareholder of Visara, Inc. (“Visara”). Visara holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories, which are licensed to Everest Medicines.

Click here to register for the virtual webcast, which will begin at 9:00 AM ET.

Call Participants:

• Sean Fu, PhD, Chief Executive Officer of NovaBridge
• Emmett T. Cunningham, Jr., MD, PhD, MPH, Co-founder and Executive Chairman of Visara and Vice Chairman of the NovaBridge Board of Directors
• Cadmus Rich, MD, MBA, Chief Medical Officer of Visara
• Carlos Quezada-Ruiz, MD, FASRS, Chair of the Scientific Advisory Board of Visara
• Nikolas JS London, MD, FACS, Managing Partner, President and Director of Research, Retina Consultants San Diego
  
  

The live and archived webcast can also be accessed by visiting the News & Events page of the NovaBridge website. A replay of the webcast will be archived for at least 90 days.

About Visara

Visara is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics. The Company is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH, a physician, innovator, entrepreneur, and investor and internationally recognized specialist in infectious and inflammatory eye disease. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

About NovaBridge

NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a potential best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.

For more information, please visit www.novabridge.com and follow us on LinkedIn.

NovaBridge Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com

NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is NovaBridge (NBP) presenting Phase 2a VIS-101 wet AMD data?

NovaBridge will present VIS-101 Phase 2a wet AMD data on March 9, 2026 at 9:00 AM ET. According to the company, the virtual business update will include clinical leadership presentations and a live webcast with a replay archived for at least 90 days.

How can investors access the NovaBridge (NBP) March 9, 2026 webcast?

Investors can register for the virtual webcast via the company's News & Events page and join live at 9:00 AM ET on March 9, 2026. According to the company, a replay will be available on the same page and archived for at least 90 days after the event.

What will NovaBridge (NBP) discuss about VIS-101 during the March 9, 2026 call?

The call will review randomized, dose-ranging Phase 2a clinical data for VIS-101 in wet AMD. According to the company, presentations will feature NovaBridge and Visara medical and scientific leaders discussing study design, dosing cohorts, and topline clinical observations.

Who will speak on the NovaBridge (NBP) VIS-101 business update call on March 9, 2026?

Speakers include NovaBridge CEO Sean Fu and Visara clinical leaders such as Emmett Cunningham Jr. and Cadmus Rich. According to the company, the roster also features external retina specialists and the chair of Visara's scientific advisory board.

What are Visara's rights to VIS-101 mentioned by NovaBridge (NBP)?

Visara holds global development and commercialization rights to VIS-101 outside Greater China and certain Asian territories. According to the company, those rights are licensed to Everest Medicines for the specified Greater China and other Asian territories.